WO1998025643A3 - Neuropeptides as modulators for cell differentiation and proliferation - Google Patents
Neuropeptides as modulators for cell differentiation and proliferation Download PDFInfo
- Publication number
- WO1998025643A3 WO1998025643A3 PCT/EP1997/006901 EP9706901W WO9825643A3 WO 1998025643 A3 WO1998025643 A3 WO 1998025643A3 EP 9706901 W EP9706901 W EP 9706901W WO 9825643 A3 WO9825643 A3 WO 9825643A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- npy
- cgrp
- granulation
- substance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0655—Chondrocytes; Cartilage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/34—Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/83—Tachykinins, e.g. substance P
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/835—Neuropeptide Y [NPY]; Peptide YY [PYY]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU58555/98A AU5855598A (en) | 1996-12-13 | 1997-12-10 | Neuropeptides as modulators for cell differentiation and proliferation |
DE19781388T DE19781388D2 (en) | 1996-12-13 | 1997-12-10 | Neuropeptides as modulators for cell differentiation and proliferation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19652033A DE19652033A1 (en) | 1996-12-13 | 1996-12-13 | Neuropeptide (CGRP) as a modulator for cell differentiation and proliferation |
DE19652033.9 | 1996-12-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1998025643A2 WO1998025643A2 (en) | 1998-06-18 |
WO1998025643A3 true WO1998025643A3 (en) | 1998-10-29 |
Family
ID=7814701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1997/006901 WO1998025643A2 (en) | 1996-12-13 | 1997-12-10 | Neuropeptides as modulators for cell differentiation and proliferation |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU5855598A (en) |
DE (2) | DE19652033A1 (en) |
WO (1) | WO1998025643A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6569654B2 (en) * | 1998-09-18 | 2003-05-27 | Massachusetts Institute Of Technology | Electroactive materials for stimulation of biological activity of stem cells |
FR2825273B1 (en) * | 2001-05-29 | 2006-11-24 | Oreal | COMPOSITION FOR THE TREATMENT OF SKIN SIGNS OF AGING |
JP2010534653A (en) * | 2007-07-27 | 2010-11-11 | イミューンリジェン バイオサイエンシズ,インク. | Method and composition for stimulating stem cell proliferation or differentiation using substance P or analogs thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0156772A2 (en) * | 1984-03-27 | 1985-10-02 | Sandoz Ag | Novel pharmaceutical use for CGRPs |
EP0188400A2 (en) * | 1985-01-16 | 1986-07-23 | Ciba-Geigy Ag | Oligopeptides, intermediates and process for their preparation |
DE3810803A1 (en) * | 1988-03-30 | 1989-10-12 | Battelle Institut E V | Process for the production of a synthetic bone material with properties intrinsic to the body |
EP0355793A2 (en) * | 1988-08-26 | 1990-02-28 | Merrell Pharmaceuticals Inc. | Neuropeptide Y agonists and partial agonists |
EP0672420A1 (en) * | 1992-08-26 | 1995-09-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Wound remedy |
US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
-
1996
- 1996-12-13 DE DE19652033A patent/DE19652033A1/en not_active Withdrawn
-
1997
- 1997-12-10 AU AU58555/98A patent/AU5855598A/en not_active Abandoned
- 1997-12-10 DE DE19781388T patent/DE19781388D2/en not_active Expired - Lifetime
- 1997-12-10 WO PCT/EP1997/006901 patent/WO1998025643A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0156772A2 (en) * | 1984-03-27 | 1985-10-02 | Sandoz Ag | Novel pharmaceutical use for CGRPs |
EP0188400A2 (en) * | 1985-01-16 | 1986-07-23 | Ciba-Geigy Ag | Oligopeptides, intermediates and process for their preparation |
DE3810803A1 (en) * | 1988-03-30 | 1989-10-12 | Battelle Institut E V | Process for the production of a synthetic bone material with properties intrinsic to the body |
EP0355793A2 (en) * | 1988-08-26 | 1990-02-28 | Merrell Pharmaceuticals Inc. | Neuropeptide Y agonists and partial agonists |
US5616562A (en) * | 1990-04-27 | 1997-04-01 | Murphy; Christopher J. | Methods and compositions using substance P to promote wound healing |
EP0672420A1 (en) * | 1992-08-26 | 1995-09-20 | Asahi Kasei Kogyo Kabushiki Kaisha | Wound remedy |
Non-Patent Citations (8)
Title |
---|
BERNARD, G.W. ET AL: "The osteogenic stimulating effect of neuroactive calcitonin gene-related peptide", PEPTIDES, vol. 11, no. 4, 1990, pages 625 - 632, XP002065012 * |
BJURHOLM A. ET AL: "Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1 and Saos-2) and primary bone cells", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 7, no. 9, 1992, pages 1011 - 1019, XP002065013 * |
BJURHOLM A. ET AL: "The ocuurence of neuropeptides at different stages of DBM-induced heterotopic bone formation", BONE AND MINERAL, vol. 10, 1990, pages 95 - 107, XP002074555 * |
DUNNICK C.A. ET AL: "Substance P has a role in neurogenic mediation of human burn wound healing", JOURNAL OF BURN CARE & REHABILITATION, vol. 17, no. 5, October 1996 (1996-10-01), pages 390 - 396, XP002074553 * |
KHALIL Z. ET AL: "Sensory peptides as Neuromodulators of wound healing in aged rats", THE JOURNALS OF GERONTOLOGY, vol. 51A, no. 5, September 1996 (1996-09-01), pages B354 - B361, XP002074552 * |
RAMESHWAR P. ET AL: "In vitro stimulatory effect of substance P on hematopoiesis", BLOOD, vol. 81, no. 2, 1993, pages 391 - 397, XP002074551 * |
TRANTOR I.R. ET AL: "The effects of neuropeptides (Calcitonin gene-related peptide and Substance P) on cultured human pulp cells", JOURNAL OF DENTAL RESEARCH, vol. 74, no. 4, 1995, pages 1066 - 1071, XP002074554 * |
VIGNERY A. ET AL: "The neuropeptide calcitonin gene related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts", BONE, vol. 18, no. 4, April 1996 (1996-04-01), pages 331 - 335, XP002065011 * |
Also Published As
Publication number | Publication date |
---|---|
DE19652033A1 (en) | 1998-06-18 |
AU5855598A (en) | 1998-07-03 |
DE19781388D2 (en) | 2001-05-10 |
WO1998025643A2 (en) | 1998-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bai et al. | Regulation of inflammatory microenvironment using a self-healing hydrogel loaded with BM-MSCs for advanced wound healing in rat diabetic foot ulcers | |
Hong et al. | Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers | |
RU2705211C2 (en) | Composition and method of treating skin scars | |
Haas et al. | Adult stem cell therapy in stroke | |
Nakamura et al. | Enhanced wound healing by topical administration of mesenchymal stem cells transfected with stromal cell-derived factor-1 | |
Tabata | Significance of release technology in tissue engineering | |
Goodarzi et al. | Adipose tissue-derived stromal cells for wound healing | |
Chehelcheraghi et al. | Effects of acellular amniotic membrane matrix and bone marrow-derived mesenchymal stem cells in improving random skin flap survival in rats | |
Günter et al. | New strategies in clinical care of skin wound healing | |
DE69615838T2 (en) | CYCLIC ACTIVE SUBSTANCE PRECONDITIONS OF PEPTIDES AND PEPTIDE NUCLEIC ACIDS WITH IMPROVED METABOLIC STABILITY AND CELL MEMBRANE PERMEABILITY | |
CN101370821A (en) | Novel peptide and uses thereof | |
DE59908745D1 (en) | PHARMACEUTICAL CICLOSPORIN FORMULATION WITH IMPROVED BIOPHARMACEUTICAL PROPERTIES, INCREASED PHYSICAL QUALITY & STABILITY AND METHOD FOR THE PRODUCTION THEREOF | |
AU7432796A (en) | Retrievable bioartificial implants | |
WO2000054799A3 (en) | Medicament for treating diabetes | |
CA2281920A1 (en) | Compositions and methods for modulating cellular nf-.kappa.b activation | |
ATE277628T1 (en) | TREATMENT OF HEMATOPOIETIC CELLS WITH CXCR4 AGONISTS | |
IL197686A0 (en) | Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith | |
CA2253287A1 (en) | A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium | |
DE69924715D1 (en) | USE OF ANGIOTENSIN ANALOGUE FOR THE PREPARATION OF A MEDICAMENT FOR INCREASING OVERLAPPING OF WHITE BLOOD CELLS AND MOBILIZING HAEMATOPOIETIC STEM CELLS AFTER CHEMOTHERAPEUTIC TREATMENT | |
Lee et al. | Effects of hepatocyte growth factor on collagen synthesis and matrix metalloproteinase production in keloids | |
James et al. | Adipose stem cells enhance excisional wound healing in a porcine model | |
Losi et al. | Healing effect of a fibrin-based scaffold loaded with platelet lysate in full-thickness skin wounds | |
AU5283890A (en) | Fibroblast growth factor (fgf)-based stabilized compositions | |
Xing et al. | Preparation of an acellular spinal cord scaffold to improve its biological properties | |
Chiu et al. | Tissue engineering-based strategies for diabetic foot ulcer management |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
REF | Corresponds to |
Ref document number: 19781388 Country of ref document: DE Date of ref document: 20010510 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19781388 Country of ref document: DE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |